Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06357754 · ClinicalTrials.gov registry record
Transgene Assay Testing Service of Tumor Samples From Patients Who Received a Bristol-Myers Squibb Manufactured Gene Modified Cell Therapy and Have a Qualifying Second Primary Malignancy
A clinical trial of Multiple Myeloma and Non-Hodgkin Lymphoma, sponsored by Bristol-Myers Squibb.
- Recruiting
- Registry status
- 50
- Enrollment target
- 8
- Study locations
NCT06357754 is a study of Multiple Myeloma and Non-Hodgkin Lymphoma that is actively recruiting participants, run by Bristol-Myers Squibb. The registered enrollment target is 50 participants, below the 547-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (91% lower). The trial reports 8 study locations across 7 states.
The verdict
NCT06357754, a study of Multiple Myeloma and Non-Hodgkin Lymphoma, is actively recruiting participants, sponsored by Bristol-Myers Squibb.
- RECRUITING
- Registry status
- 50 participants
- Enrollment target
- 8
- Study locations
Study Summary
The purpose of this transgene assay testing service is to evaluate tumor samples for transgene levels in patients who received a commercially available Bristol-Myers Squibb manufactured gene modified cellular therapy and have reported a qualifying second malignancy.
Conditions Studied
Interventions
- BIOLOGICAL Idecabtagene vicleucel
- BIOLOGICAL Lisocabtagene maraleucel
Study Locations (8)
Other
- Universitaetsklinikum Essen (AoR) - Essen
- Kantonsspital Aarau - Aarau
Oregon
- Local Institution - 0016 - Portland
Texas
- Ut Southwestern - Dallas
Utah
- Huntsman Cancer Institute at the University of Utah - Salt Lake City
Wisconsin
- Local Institution - 0004 - Madison
Aichi-ken
- Toyokawa City Hospital - Toyokawa
Kumamoto
- Local Institution - 0003 - Kumamoto
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2023-10-06 |
| Est. Completion | 2038-10-06 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06357754
The ClinicalTrials.gov registry entry for NCT06357754 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 547-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (91% lower). The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Multiple Myeloma appearing as the primary indexed condition, and to 2 interventions - of which Idecabtagene vicleucel is the first listed.
NCT06357754 reports 8 study locations spanning 7 distinct geographic areas - top geographies include Other, Oregon, Texas.
Frequently Asked Questions
What is clinical trial NCT06357754 about?
NCT06357754 is a clinical study titled "Transgene Assay Testing Service of Tumor Samples From Patients Who Received a Bristol-Myers Squibb Manufactured Gene Modified Cell Therapy and Have a Qualifying Second Primary Malignancy". The purpose of this transgene assay testing service is to evaluate tumor samples for transgene levels in patients who received a commercially available Bristol-Myers Squibb manufactured gene modified cellular therapy and have reported a qualifying second malignancy.
What is the current status of trial NCT06357754?
This trial is currently recruiting. The enrollment target is 50 participants. The study started on 2023-10-06. Estimated completion is 2038-10-06.
What conditions does trial NCT06357754 study?
This clinical trial studies the following conditions: Multiple Myeloma, Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukaemia.
What interventions are being tested in trial NCT06357754?
The interventions under investigation include: Idecabtagene vicleucel (BIOLOGICAL), Lisocabtagene maraleucel (BIOLOGICAL).
Who is sponsoring clinical trial NCT06357754?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06357754 being conducted?
This trial has 8 study locations across Oregon, Texas, Utah, Wisconsin, Aichi-ken. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Multiple Myeloma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Real World Treatment Experience of Patients With Breast, Lung, Ovarian, Multiple Myeloma, or Acute Myelogenous Leukemia Using Remote Symptom Monitoring
RECRUITING
-
A Study of Whether Ide-cel (bb2121) Can Be Made From People With Multiple Myeloma Who Have Had a Hematopoietic Cell Transplant
RECRUITING · Phase 2
-
A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatments
RECRUITING · Phase 1
-
A Study of a Plant-Based Diet and Dietary Supplements in People With Smoldering Multiple Myeloma (SMM) or Monoclonal Gammopathy of Undetermined Significance (MGUS)
RECRUITING · NA
-
Development of a Research Infrastructure for Understanding and Addressing Multiple Myeloma Disparities
RECRUITING
-
Ascertainment of Families for Genetic Studies of Familial Lymphoproliferative Disorders
RECRUITING
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.